NEW YORK, May 30, 2017 /PRNewswire/ --
The Generic Drugs market can be segmented into biosimilars, simple generic,and super generic. Based on its therapeutics applications, the industry can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. This
Hatfield, the UK-based Mylan N.V.'s stock saw a slight decline of 0.28%, finishing last Friday's trading session at $39.72. A total volume of 3.97 million shares was traded. The Company's shares have gained 5.30% in the last month and 4.12% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 2.04% and 0.68%, respectively. Additionally, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have a Relative Strength Index (RSI) of 57.24.
On May 22nd, 2017, research firm Barclays upgraded the Company's stock rating from 'Equal Weight' to 'Overweight' while revising its previous target price from $47 a share to $50 a share.
On May 23rd, 2017, Mylan and Theravance Biopharma, Inc. announced the presentation of additional efficacy and safety data from the three-month, pivotal Phase-3 studies of revefenacin (TD-4208) at the American Thoracic Society International Conference in Washington, D.C. Revefenacin is an investigational, long-acting, muscarinic antagonist, and a proposed once-daily, nebulized bronchodilator in development for the treatment of chronic obstructive pulmonary disease. See our free and comprehensive research report on MYL at:
Shares in Dublin, Ireland headquartered Allergan PLC ended at $223.12, down 0.55% from the last trading session. The stock recorded a trading volume of 1.70 million shares. The Company's shares have advanced 6.24% since the start of this year. The stock is trading 1.71% below its 200-day moving average. Moreover, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have an RSI of 34.23.
On May 10th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $279 a share to $284 a share.
On May 16th, 2017, Allergan announced the results of a new, online, eye-language survey of 1,019 adult Americans that found 53% of respondents saying that the eyes are the first facial feature they notice about another person. The "A Look at Eye Language" online survey was conducted by Kelton Global on behalf of Allergan, in support of the brand's Eyepowerment campaign to raise awareness for Chronic Dry Eye disease. AGN free research report PDF is just a click away at:
On Friday, shares in Dublin, Ireland headquartered Horizon Pharma PLC recorded a trading volume of 3.96 million shares. The stock rose 2.31%, closing the day at $10.20. The Company's shares are trading 25.58% below their 50-day moving average. Additionally, shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the US and internationally, have an RSI of 30.58.
On May 09th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $35 a share to $20 a share.
On May 25th, 2017, Horizon Pharma announced that it has been selected to Fortune's "Best Workplaces in Chicago" list. The Company ranked number two on the list of the best small and medium-sized companies. Sign up for your complimentary report on HZNP at:
At the close of trading on Friday, shares in San Diego, California headquartered Neurocrine Biosciences Inc. recorded a trading volume of 1.63 million shares, which was higher than their three months average volume of 1.39 million shares. The stock finished the session 4.99% lower at $46.22. The Company's shares have gained 2.42% in the previous three months and 19.43% since the start of this year. The stock is trading below its 200-day moving average by 0.68%. Furthermore, shares of Neurocrine Biosciences, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the US and internationally, have an RSI of 35.59.
On May 23rd, 2017, Neurocrine Biosciences announced that the initial Phase-II Tourette syndrome T-Force GREEN study of INGREZZA® (valbenazine), a small molecule VMAT2 inhibitor, did not meet its primary endpoint. The pre-specified primary endpoint was the change-from-baseline between the placebo and active groups in the Yale Global Tic Severity Scale at Week 6 in the intent-to-treat population. Register for free on Stock-Callers.com and download the latest research report on NBIX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All